HRP20191942T1 - Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije - Google Patents

Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije Download PDF

Info

Publication number
HRP20191942T1
HRP20191942T1 HRP20191942TT HRP20191942T HRP20191942T1 HR P20191942 T1 HRP20191942 T1 HR P20191942T1 HR P20191942T T HRP20191942T T HR P20191942TT HR P20191942 T HRP20191942 T HR P20191942T HR P20191942 T1 HRP20191942 T1 HR P20191942T1
Authority
HR
Croatia
Prior art keywords
purin
amino
methyl
propylsulfonimidoyl
oxo
Prior art date
Application number
HRP20191942TT
Other languages
English (en)
Croatian (hr)
Inventor
Chungen Liang
Kun MIAO
Jianping Wang
Hongying Yun
Xiufang ZHENG
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191942(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20191942T1 publication Critical patent/HRP20191942T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20191942TT 2015-05-08 2016-05-04 Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije HRP20191942T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
EP16720421.3A EP3294740B1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
HRP20191942T1 true HRP20191942T1 (hr) 2020-01-10

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191942TT HRP20191942T1 (hr) 2015-05-08 2016-05-04 Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije

Country Status (32)

Country Link
US (3) US9708325B2 (https=)
EP (1) EP3294740B1 (https=)
JP (1) JP6738352B2 (https=)
KR (1) KR102690131B1 (https=)
CN (1) CN107580596B (https=)
AR (1) AR104528A1 (https=)
AU (3) AU2016260683B2 (https=)
BR (1) BR112017023959B1 (https=)
CA (1) CA2982704C (https=)
CL (1) CL2017002745A1 (https=)
CO (1) CO2017009994A2 (https=)
CR (1) CR20170496A (https=)
DK (1) DK3294740T3 (https=)
ES (1) ES2753777T3 (https=)
HR (1) HRP20191942T1 (https=)
HU (1) HUE045906T2 (https=)
IL (2) IL254947B (https=)
LT (1) LT3294740T (https=)
MX (2) MX376761B (https=)
MY (1) MY182353A (https=)
NZ (2) NZ775222A (https=)
PE (1) PE20171620A1 (https=)
PH (1) PH12017502009A1 (https=)
PL (1) PL3294740T3 (https=)
PT (1) PT3294740T (https=)
RS (1) RS59435B1 (https=)
RU (1) RU2745269C2 (https=)
SG (1) SG10202108841YA (https=)
SI (1) SI3294740T1 (https=)
TW (2) TWI706954B (https=)
UA (1) UA120450C2 (https=)
WO (1) WO2016180695A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
AU2017320742B2 (en) 2016-08-29 2021-08-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
CN109715214B (zh) 2016-09-13 2022-03-04 豪夫迈·罗氏有限公司 Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ. ホフマン-ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
RU2020131012A (ru) * 2018-02-28 2022-03-28 Ф. Хоффманн-Ля Рош Аг 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
JP7695885B2 (ja) * 2019-02-12 2025-06-19 アンブルックス,インコーポレイテッド 抗体-tlrアゴニストコンジュゲートを含有する組成物、その方法、及び使用
JP7581336B2 (ja) 2019-09-20 2024-11-12 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 硫黄及びスルホキシミン含有置換基を有する殺有害生物的に活性な複素環式誘導体
US20230131192A1 (en) * 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP2023512204A (ja) * 2020-01-27 2023-03-24 ブリストル-マイヤーズ スクイブ カンパニー トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
CN119604517A (zh) 2022-07-14 2025-03-11 豪夫迈·罗氏有限公司 用于治疗癌症的磷酰基嘌呤酮化合物
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
EP1888587A1 (en) 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
ES2467108T3 (es) * 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TW201636330A (zh) * 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
RS57851B1 (sr) * 2011-11-09 2018-12-31 Janssen Sciences Ireland Uc Purinski derivati za tretman viralnih infekcija
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
AU2017320742B2 (en) * 2016-08-29 2021-08-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Also Published As

Publication number Publication date
PT3294740T (pt) 2019-10-29
CN107580596B (zh) 2020-07-14
AR104528A1 (es) 2017-07-26
NZ775222A (en) 2024-09-27
JP6738352B2 (ja) 2020-08-12
HUE045906T2 (hu) 2020-01-28
LT3294740T (lt) 2019-11-25
AU2016260683B2 (en) 2020-10-29
TW201716410A (zh) 2017-05-16
NZ735648A (en) 2023-06-30
SG10202108841YA (en) 2021-09-29
KR20180003612A (ko) 2018-01-09
EP3294740B1 (en) 2019-09-04
US11242345B2 (en) 2022-02-08
US20200109144A1 (en) 2020-04-09
US20170275286A1 (en) 2017-09-28
KR102690131B1 (ko) 2024-07-31
MX2017014033A (es) 2018-03-01
CN107580596A (zh) 2018-01-12
HK1247925A1 (zh) 2018-10-05
CR20170496A (es) 2017-12-05
CA2982704A1 (en) 2016-11-17
RU2745269C2 (ru) 2021-03-22
MX2020010949A (es) 2022-06-16
ES2753777T3 (es) 2020-04-14
UA120450C2 (uk) 2019-12-10
IL280769A (en) 2021-04-29
DK3294740T3 (da) 2019-11-04
MY182353A (en) 2021-01-20
MX393198B (es) 2025-03-19
TW202108584A (zh) 2021-03-01
AU2016260683A1 (en) 2017-10-12
RU2017142577A (ru) 2019-06-10
MX376761B (es) 2025-03-07
IL254947A0 (en) 2017-12-31
RS59435B1 (sr) 2019-11-29
JP2018515509A (ja) 2018-06-14
IL280769B1 (en) 2023-03-01
US20160326177A1 (en) 2016-11-10
BR112017023959A2 (pt) 2018-07-17
TWI768467B (zh) 2022-06-21
PH12017502009A1 (en) 2018-03-26
EP3294740A1 (en) 2018-03-21
PL3294740T3 (pl) 2020-03-31
US9708325B2 (en) 2017-07-18
CA2982704C (en) 2023-10-24
CL2017002745A1 (es) 2018-05-18
SI3294740T1 (sl) 2019-12-31
TWI706954B (zh) 2020-10-11
RU2017142577A3 (https=) 2019-10-31
US10399983B2 (en) 2019-09-03
BR112017023959B1 (pt) 2023-05-02
AU2020256348B2 (en) 2022-06-16
IL280769B2 (en) 2023-07-01
AU2022204666A1 (en) 2022-07-21
IL254947B (en) 2021-02-28
WO2016180695A1 (en) 2016-11-17
CO2017009994A2 (es) 2018-02-20
PE20171620A1 (es) 2017-11-02
AU2020256348A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
HRP20191942T1 (hr) Novi sulfonimidoilpurinonski spojevi i derivati za liječenje i profilaksu virusne infekcije
JP2018515509A5 (https=)
ES2453591T3 (es) Derivado de uracilo o timina para el tratamiento de la hepatitis C
HRP20240161T1 (hr) Inhibitor atr i njegova primjena
RU2018123779A (ru) Новые соединения
SI2970155T1 (en) INHIBITORS INDOLEAMIN 2,3-DIOXYGENESIS (IDO)
JP2017537949A5 (https=)
HRP20161177T1 (hr) Modulator glukagonskog receptora
JP2018507861A5 (https=)
JP2016523923A5 (https=)
JP2016506962A5 (https=)
PE20181144A1 (es) Derivados de heteroarilo como inhibidores de parp
PE20170004A1 (es) Inhibidores de biaril cinasa
JP2009538897A5 (https=)
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
JP2018518522A5 (https=)
JP2012509263A5 (https=)
ME00427B (me) N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze
JP2013544893A5 (https=)
JP2017517538A5 (https=)
RU2018114077A (ru) Биарильное производное и содержащее его лекарственное средство
IL283368B1 (en) An imidazo[1,2-b]pyridazin-7-yl-urea compound and a medicine comprising the compound
RU2019102674A (ru) ПИРАЗОЛО[1,5-a]ПИРИМИДИНОВОЕ СОЕДИНЕНИЕ
JP2022017461A5 (https=)
JP2016540803A5 (https=)